bioRxivBioinformaticsPreprint
OmicsPharLeuDB: an integrative database for mining pharmacogenomic data in acute lymphoblastic leukemia
Abstract
Leukemia is one of the most common hematological malignancies in children. Recent cancer pharmacogenomic studies profiled large panels of cell lines against hundreds of approved drugs and experimental chemical compounds. However, until now, no comprehensive databases have been specifically designed for leukemia. Therefore, we have developed OmicsPharLeuDB (mugpeng.shinyapps.io/leu_web_english_peng_v2/), a database that includes the largest published studies investigating the viability response of human leukemia cell lines to chemical compound treatment, and the association between drug sensitivity and multi-omics, and also provides a user-friendly interactive website allowing the user to assess drug sensitivity data from a different platform and find the potential relationship between drugs and omics.
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies
Petr Smirnov, Victor Kofia, … Benjamin Haibe‐Kains·Nucleic Acids ResearchPeer-reviewed·Sep 27, 2017
- DBPOM: a comprehensive database of pharmaco-omics for cancer precision medicine
- Pharmaco-Pheno-Multiomic Integration Reveals Biomarker Profiles and Therapeutic Response Prediction Models in Leukemia and Ovarian Cancer
G. Silberberg, B. Walling, … M. RItchie·bioRxiv·Jun 14, 2022
- AMLdb: A comprehensive multi-omics platform to understand the pathogenesis and discover biomarkers for acute myeloid leukemia
Keerthana Vinod Kumar, Ambuj Kumar, … Rahul Kumar·bioRxiv·May 19, 2023
- Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia
Y.-Y. Ding, H. Kim, … K. Tan·bioRxiv·Jan 6, 2021
- Utilizing proteomics and phosphoproteomics to predict ex vivo drug sensitivity across genetically diverse AML patients
Sara J.C. Gosline, Cristina E. Tognon, … Karin Rodland·bioRxiv·Jun 4, 2021